Chemotherapy-free Treatment of Patients with BRAFV600E-mutant metastatic Colorectal Cancer

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / 06期
关键词：
BRAF; VEMURAFENIB; INHIBITION;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Chemotherapy-Free Intervals for Patients With Metastatic Colorectal Cancer Remain an Option
    Maughan, Tim
    Adams, Richard
    Wilson, Richard
    Seymour, Matthew
    Meade, Angela
    Kaplan, Richard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (17) : E275 - E276
  • [32] Chemotherapy-free intervals (CFI) in patients with metastatic colorectal cancer (MRC).
    Plantade, A.
    Afchain, P.
    Tournigand, C.
    Maindrault-Goebel, F.
    Chibaudel, B.
    Bourges, O.
    Perez-Staub, N.
    Larsen, A.
    Louvet, C.
    De Gramont, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 166S - 166S
  • [33] Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer
    Huijberts, Sanne C. F. A.
    van Geel, Robin M. J. M.
    Bernards, Rene
    Beijnen, Jos H.
    Steeghs, Neeltje
    [J]. FUTURE ONCOLOGY, 2020, 16 (06) : 161 - 174
  • [34] Erratum: Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model
    Daniel C. Kirouac
    Gabriele Schaefer
    Jocelyn Chan
    Mark Merchant
    Christine Orr
    Shih-Min A. Huang
    John Moffat
    Lichuan Liu
    Kapil Gadkar
    Saroja Ramanujan
    [J]. npj Systems Biology and Applications, 3
  • [35] Confined copper depletion via a hydrogel platform for reversing dabrafenib/cetuximab resistance in BRAFV600E-mutant V600E-mutant colorectal cancer
    Wang, Jue
    Sun, Xiangshi
    Zhao, Zhiwen
    Wang, Guanru
    Wang, Dangge
    Li, Yaping
    [J]. JOURNAL OF CONTROLLED RELEASE, 2024, 375
  • [36] Impact of Online Tumor Board Simulation for Optimizing Testing and Treatment of Patients with BRAFV600E- mutant Metastatic Colorectal Cancer
    Kelly, M.
    Beumer, K.
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2023, 160 : S42 - S42
  • [37] Impact of Online Tumor Board Simulation for Optimizing Testing and Treatment of Patients with BRAFV600E- mutant Metastatic Colorectal Cancer
    Kelly, M.
    Beumer, K.
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2023, 160 : S42 - S42
  • [38] Chemotherapy-Free Intervals for Patients With Metastatic Colorectal Cancer Remain an Option Reply
    Hochster, Howard S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (17) : E277 - E277
  • [39] Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAFV600E-mutant metastatic colorectal carcinoma
    Connolly, K.
    Brungs, D.
    Szeto, E.
    Epstein, R. J.
    [J]. CURRENT ONCOLOGY, 2014, 21 (01) : E151 - E154
  • [40] Antitumor activity of the new tyrphostin briva against BRAFV600E-mutant colorectal carcinoma cells
    Saleh, Khaled
    Al Sakhen, Mai
    Kanaan, Sana
    Yasin, Salem
    Hoepfner, Michael
    Tahtamouni, Lubna
    Biersack, Bernhard
    [J]. INVESTIGATIONAL NEW DRUGS, 2023, 41 (06) : 791 - 801
12345